Limits...
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D, GO-MONO study gro - Ann. Rheum. Dis. (2012)

Bottom Line: Week 14 ACR20 response rates were significantly greater in groups 2 (51/101 (50.5%)) and 3 (60/102 (58.8%)) than in group 1 (20/105 (19.0%); p<0.0001 for both), as were ACR50 and ACR70 response rates.No deaths or cases of tuberculosis were reported through week 24.Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Keio University, Shinjuku-ku, Tokyo, Japan. tsutake@z5.keio.jp

ABSTRACT

Objective: To evaluate the efficacy and safety of golimumab 50 and 100 mg monotherapy in Japanese patients with active rheumatoid arthritis (RA) despite treatment with disease-modifying antirheumatic drugs (DMARDs).

Methods: A total of 316 patients were randomised to receive subcutaneous injections every 4 weeks of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3); group 1 crossed over to golimumab 50 mg at week 16. The primary end point was the proportion of patients achieving ≥20% improvement in the American College of Rheumatology criteria (ACR20) at week 14. ACR50 and ACR70 response rates were also measured. Adverse events (AEs) were monitored throughout the study.

Results: Demographics were similar across groups; the mean age was 52 years and 81.8% of patients (252/308) were female. Week 14 ACR20 response rates were significantly greater in groups 2 (51/101 (50.5%)) and 3 (60/102 (58.8%)) than in group 1 (20/105 (19.0%); p<0.0001 for both), as were ACR50 and ACR70 response rates. After placebo crossover at week 16, week 24 ACR response rates were similar in groups 1 and 2. Through week 16, 63.8% of patients in group 1, 62.4% in group 2 and 60.8% in group 3 had AEs and 1.9%, 1.0% and 2.0% had serious AEs. After week 16, one malignancy was reported (breast cancer, group 3). Infections were the most common AEs. No deaths or cases of tuberculosis were reported through week 24.

Conclusions: Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

Show MeSH

Related in: MedlinePlus

Cumulative probability plot of changes in van der Heijde-Sharp (vdH–S) scores from baseline to week 24 Data from one patient in the golimumab 100 mg group who had an atypically large change in vdH–S score were excluded.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3756456&req=5

ANNRHEUMDIS2012201796F2: Cumulative probability plot of changes in van der Heijde-Sharp (vdH–S) scores from baseline to week 24 Data from one patient in the golimumab 100 mg group who had an atypically large change in vdH–S score were excluded.

Mentions: At week 24, increases in erosion, joint space narrowing and total vdH–S scores were seen in all three groups (table 2), with smaller changes in erosion and total scores in groups 2 and 3, indicating less radiographic progression than in group 1, as shown in the probability plot (figure 2). In the a priori analysis (ANCOVA), no significant differences were seen in mean changes between groups 2 and 3 and group 1 at week 24. In the post hoc ANOVA using normalised scores, no significant differences were seen between groups 2 and 1. Although increases from baseline were observed in both groups 3 and 1, the mean changes in erosion and total vdH–S scores in group 3 were statistically significantly smaller than those in group 1 (1.1 vs 1.3, p=0.0316 and 2.1 vs 2.6, p=0.0043, respectively). Also, the median changes in total vdH–S scores followed a trend, showing less radiographic progression in groups 2 and 3 than in group 1 (0.5 and 0.0, respectively, vs 1.0).


Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D, GO-MONO study gro - Ann. Rheum. Dis. (2012)

Cumulative probability plot of changes in van der Heijde-Sharp (vdH–S) scores from baseline to week 24 Data from one patient in the golimumab 100 mg group who had an atypically large change in vdH–S score were excluded.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3756456&req=5

ANNRHEUMDIS2012201796F2: Cumulative probability plot of changes in van der Heijde-Sharp (vdH–S) scores from baseline to week 24 Data from one patient in the golimumab 100 mg group who had an atypically large change in vdH–S score were excluded.
Mentions: At week 24, increases in erosion, joint space narrowing and total vdH–S scores were seen in all three groups (table 2), with smaller changes in erosion and total scores in groups 2 and 3, indicating less radiographic progression than in group 1, as shown in the probability plot (figure 2). In the a priori analysis (ANCOVA), no significant differences were seen in mean changes between groups 2 and 3 and group 1 at week 24. In the post hoc ANOVA using normalised scores, no significant differences were seen between groups 2 and 1. Although increases from baseline were observed in both groups 3 and 1, the mean changes in erosion and total vdH–S scores in group 3 were statistically significantly smaller than those in group 1 (1.1 vs 1.3, p=0.0316 and 2.1 vs 2.6, p=0.0043, respectively). Also, the median changes in total vdH–S scores followed a trend, showing less radiographic progression in groups 2 and 3 than in group 1 (0.5 and 0.0, respectively, vs 1.0).

Bottom Line: Week 14 ACR20 response rates were significantly greater in groups 2 (51/101 (50.5%)) and 3 (60/102 (58.8%)) than in group 1 (20/105 (19.0%); p<0.0001 for both), as were ACR50 and ACR70 response rates.No deaths or cases of tuberculosis were reported through week 24.Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Keio University, Shinjuku-ku, Tokyo, Japan. tsutake@z5.keio.jp

ABSTRACT

Objective: To evaluate the efficacy and safety of golimumab 50 and 100 mg monotherapy in Japanese patients with active rheumatoid arthritis (RA) despite treatment with disease-modifying antirheumatic drugs (DMARDs).

Methods: A total of 316 patients were randomised to receive subcutaneous injections every 4 weeks of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3); group 1 crossed over to golimumab 50 mg at week 16. The primary end point was the proportion of patients achieving ≥20% improvement in the American College of Rheumatology criteria (ACR20) at week 14. ACR50 and ACR70 response rates were also measured. Adverse events (AEs) were monitored throughout the study.

Results: Demographics were similar across groups; the mean age was 52 years and 81.8% of patients (252/308) were female. Week 14 ACR20 response rates were significantly greater in groups 2 (51/101 (50.5%)) and 3 (60/102 (58.8%)) than in group 1 (20/105 (19.0%); p<0.0001 for both), as were ACR50 and ACR70 response rates. After placebo crossover at week 16, week 24 ACR response rates were similar in groups 1 and 2. Through week 16, 63.8% of patients in group 1, 62.4% in group 2 and 60.8% in group 3 had AEs and 1.9%, 1.0% and 2.0% had serious AEs. After week 16, one malignancy was reported (breast cancer, group 3). Infections were the most common AEs. No deaths or cases of tuberculosis were reported through week 24.

Conclusions: Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

Show MeSH
Related in: MedlinePlus